Related Experiment Video
Updated: Jul 7, 2026
10:26
Monitoring Cell-to-cell Transmission of Prion-like Protein Aggregates in Drosophila Melanogaster
Published on: March 12, 2018
Abeta42 mutants with different aggregation profiles induce distinct pathologies in Drosophila
Koichi Iijima1, Hsueh-Cheng Chiang, Stephen A Hearn
1Cold Spring Harbor Laboratory, Cold Spring Harbor, New York, USA. Koichi.Iijima@jefferson.edu
Plos One
|February 28, 2008
Summary
Altering amyloid-beta-42 (Abeta42) aggregation in Alzheimer's disease models changes toxicity levels and induces distinct brain pathologies. Modifying Abeta42 aggregation not only affects toxicity but also qualitatively alters disease progression and symptoms.
Area of Science:
- Neuroscience
- Biochemistry
- Genetics
Background:
- Amyloid-beta-42 (Abeta42) aggregation in the brain is a key feature of Alzheimer's disease (AD).
- Different Abeta aggregate forms may have varying pathogenic effects.
- Targeting Abeta aggregation is a potential therapeutic strategy for AD.
Purpose of the Study:
- To investigate how mutations affecting Abeta42 aggregation propensity influence its pathogenicity in vivo.
- To compare the effects of an aggregation-prone mutant (Abeta42Arc) and an aggregation-suppressing mutant (Abeta42art) with wild-type Abeta42.
Main Methods:
- Utilized Drosophila melanogaster as a model organism to study Abeta42 aggregation and its effects.
- Introduced human Abeta42 wild-type, Abeta42Arc, and Abeta42art mutations into the Drosophila brain.
- Assessed behavioral deficits (locomotor dysfunction, memory defects), survival rates, and neuropathological changes (neuron loss, neurite degeneration).
- Visualized Abeta aggregate distribution using Thioflavin S staining.
Main Results:
- Abeta42Arc showed increased oligomer and deposit formation compared to wild-type Abeta42, while Abeta42art showed reduced formation.
- Locomotor dysfunction and premature death correlated positively with aggregation tendency.
- Surprisingly, Abeta42art induced earlier memory defects than wild-type Abeta42.
- Distinct pathologies were observed: Abeta42Arc caused more neuron loss, Abeta42art led to severe neurite degeneration, and wild-type Abeta42 affected both.
- Aggregate distribution varied: Abeta42Arc in cell bodies, Abeta42art in neurites, and wild-type Abeta42 in both.
Conclusions:
- The aggregation propensity of Abeta42 significantly influences its in vivo pathogenicity.
- Modulating Abeta42 aggregation not only alters toxicity levels but also induces qualitatively different neuropathological outcomes.
- These findings highlight the complex role of Abeta aggregation in Alzheimer's disease pathogenesis and suggest that therapeutic strategies must consider the specific aggregate forms induced.
